查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1969476

阻塞性細支氣管炎症候群市場：依藥物類別、治療類型、給藥方式、最終用戶和通路分類－2026-2032年全球預測

Bronchiolitis Obliterans Syndrome Market by Drug Class, Procedure Type, Delivery Mode, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，阻塞性細支氣管炎市場價值將達到 7,943 萬美元，到 2026 年將成長至 9,255 萬美元，到 2032 年將達到 1.4154 億美元，複合年成長率為 8.60%。

主要市場統計數據
基準年 2025 7943萬美元
預計年份：2026年 9255萬美元
預測年份 2032 1.4154億美元
複合年成長率 (%) 8.60%

對阻塞性細支氣管炎進行全面介紹：以臨床複雜性、護理路徑和跨學科策略要求為框架。

阻塞性細支氣管炎在移植醫學、慢性肺部疾病治療和免疫學領域都面臨多重挑戰。作為一種進行性性小氣道纖維性阻塞性疾病，它主要發生於肺移植術後或嚴重感染/毒性暴露後，導致肺功能持續下降和發病率增加。為了因應臨床上對早期發現移植物功能障礙並採取精準治療策略日益成長的需求，近年來，相關研究活動和治療方法的進步顯著加快。

診斷方法、治療策略和護理方式的變革性變化正在重塑慢性氣道移植保護的臨床演算法和操作重點。

支氣管移植保護和慢性氣道疾病管理領域正經歷變革，這主要得益於診斷準確性、治療標靶化和醫療服務模式的進步。結合生理監測、影像學和新興生物標記檢測的改進型監測策略，能夠早期發現小氣道損傷，並為及時干預提供機會。同時，治療策略也從廣泛的免疫抑制療法發展到平衡排斥反應預防、感染風險降低和代謝安全性的方案最佳化。

評估貿易政策和關稅制度的變化如何影響關鍵肺部護理材料的供應鏈重新設計、本地採購和採購韌性。

近期關稅措施和貿易政策調整為跨境供應鏈和籌資策略帶來了新的考量，影響到用於治療阻塞性細支氣管症候群的治療藥物、醫療設備和專用設備。進口關稅和海關程序可能會影響吸入裝置、靜脈輸液幫浦和專用移植保存材料的採購決策，進而影響產品的供應和採購計畫。因此，醫療機構和製造商正在重新評估其製造地並尋求供應商多元化，以確保治療的連續性。

基於將治療層級、給藥途徑、劑量形式、護理環境和分銷網路聯繫起來的分段觀點，確定了干涉點。

一個考慮細微差異的細分框架揭示了臨床需求、採購緊迫性和治療創新在藥物類別、治療類型、給藥途徑、最終用戶和分銷管道之間的交集。在藥物類別中，皮質類固醇是核心藥物，可分為吸入劑和全身給藥劑。同時，免疫抑制劑需要區分抗代謝藥物和Calcineurin酶抑制劑。此外，臨床證據的差異也反映在阿奇黴素和克拉黴素的使用上。治療類型包括用於監測和介入的支氣管鏡檢查、肺移植（包括單肺移植和雙肺移植）以及在住院和門診環境中提供的肺康復，以支持功能恢復。

臨床網路、監管途徑和供應鏈現實方面的區域差異是影響全球醫療保健區域准入和實施策略的關鍵因素。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的臨床實務模式、監管路徑、報銷結構和供應鏈策略均有顯著影響。在美洲，臨床網路傾向於將移植專業知識集中在專業機構，從而支持手術全期護理的整合和監測性支氣管鏡檢查的積極應用。同時，商業和報銷環境正在推動在住院和門診環境中提供長期治療。然而，在歐洲、中東和非洲，法規結構和報銷機制存在差異，需要靈活的臨床證據包和區域合作來應對不同的醫療保健系統優先事項。

企業原型、合作模式和實證差異化策略定義了慢性氣道護理領域的競爭和供應韌性。

阻塞性細支氣管疾病（OBTI）領域主要企業的發展趨勢體現了製藥創新者、醫療設備製造商、診斷研發公司、專業契約製造以及領先的移植和呼吸中心之間的融合。製藥研發公司正在探索改進免疫調節療法，並重新利用現有藥物治療慢性氣道發炎；醫療設備製造商則投資於吸入平台和支氣管鏡技術，以提高標靶給藥和診斷效率。診斷公司正在開發用於早期檢測移植損傷的生物標記和檢測平台，這將影響治療時機和臨床試驗設計。

領導者將監測主導的臨床路徑、供應鏈韌性和綜合解決方案開發相結合，制定可操作的策略重點，以改善長期治療效果。

產業領導者應優先考慮整合臨床證據、供應鏈韌性和相關人員參與的策略，以實際改善患者預後。首先，投資於結合生理檢測、影像學和新興生物標記的多模態監測方法，以便更早進行實證干預。其次，評估能夠提高用藥依從性和治療指標的給藥方式（特別是吸入系統和控釋輸注技術），並最佳化治療方法。

結合文獻整合、專家訪談和結構化檢驗的多方法研究途徑檢驗了臨床、營運和細分方面的見解。

本研究採用多方法結合的方式，包括嚴謹的二手文獻綜述、對臨床和供應鏈專家的訪談以及結構化資料整合，以確保分析的嚴謹性和實用性。二手資料包括同行評審的臨床研究、專業學會指南、監管文件以及醫療設備和治療藥物的技術規範。這些資料用於建立證據基礎，並確定需要初步檢驗的領域。

為了維持肺功能並提高以患者為中心的治療效果，關鍵的綜合見解強調早期檢測、標靶治療和強大的治療交付系統的整合。

總之，阻塞性細支氣管炎需要採取協調一致的策略，包括早期發現、標靶治療和完善的治療系統。臨床進展得益於監測技術的改進和更精細的治療策略，這些策略兼顧了免疫調節和安全性。同時，手術創新和復健計畫最佳化了病患的復健路徑，而給藥方式的進步則有助於提高病患的用藥依從性和給藥準確性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章阻塞性細支氣管炎症候群市場：依藥物類別分類

  • 皮質類固醇
    • 吸入劑
    • 系統
  • 免疫抑制劑
    • 抗代謝物
    • Calcineurin抑制劑
  • 大環內酯類
    • 阿奇黴素
    • 克拉黴素

第9章阻塞性細支氣管炎症候群市場（依手術類型分類）

  • 支氣管鏡檢查
  • 肺移植
  • 肺康復

第10章：阻塞性細支氣管炎症候群市場：依給藥途徑分類

  • 吸入
    • 吸入器
    • 噴霧器
  • 靜脈注射
    • Bolus
    • 靜脈注射
  • 口服
    • 膠囊
    • 藥片

第11章阻塞性細支氣管炎症候群市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所
    • 呼吸系統醫療設備
    • 移植中心

第12章阻塞性細支氣管炎症候群市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章阻塞性細支氣管炎症候群市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章阻塞性細支氣管炎症候群市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章阻塞性細支氣管炎症候群市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國阻塞性細支氣管炎疾病市場

第17章：中國阻塞性細支氣管炎綜合症市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Mallinckrodt plc
  • Merck & Co., Inc.
  • Novartis AG
  • Omron Corporation
  • PARI GmbH
  • Pfizer Inc.
  • Sanofi SA
  • Sensirion AG
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-535C62918A91

The Bronchiolitis Obliterans Syndrome Market was valued at USD 79.43 million in 2025 and is projected to grow to USD 92.55 million in 2026, with a CAGR of 8.60%, reaching USD 141.54 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 79.43 million
Estimated Year [2026] USD 92.55 million
Forecast Year [2032] USD 141.54 million
CAGR (%) 8.60%

An integrated introduction to bronchiolitis obliterans syndrome that frames clinical complexity, care pathways, and strategic imperatives across disciplines

Bronchiolitis obliterans syndrome presents a multifaceted challenge at the intersection of transplant medicine, chronic pulmonary care, and immunology. As a progressive fibro-obliterative condition of the small airways, it most commonly arises in the context of lung transplantation and severe post-infectious or toxic exposures, producing sustained declines in lung function and increased morbidity. The clinical imperative to detect early graft dysfunction and to intervene with precise therapeutic strategies has intensified research activity and care pathway evolution in recent years.

Consequently, the therapeutic landscape is characterized by heterogeneous use of corticosteroids, immunosuppressants, and macrolide antibiotics, alongside procedural interventions such as bronchoscopy, lung transplantation, and pulmonary rehabilitation. These modalities interact with diverse delivery modes, including inhalation, intravenous, and oral administration, and depend heavily on care settings ranging from ambulatory surgery centers to specialized transplant clinics. Therefore, stakeholders must understand both the biological underpinnings and the care delivery architecture to design interventions that improve outcomes.

This introduction sets the stage for an integrated examination of clinical advances, policy changes, supply chain dynamics, and stakeholder behaviors that collectively shape patient trajectories. By focusing on translational insights and operational implications, the forthcoming analysis guides clinicians, product strategists, and health system leaders toward high-impact choices in prevention, diagnosis, and long-term management.

Transformative shifts in diagnostics, therapeutic strategies, and care delivery that are reshaping clinical algorithms and operational priorities for chronic airway graft protection

The landscape for bronchial graft protection and chronic airway disease management is undergoing transformative shifts driven by advances in diagnostic precision, therapeutic targeting, and care delivery models. Improved surveillance strategies now combine physiologic monitoring with imaging and emerging biomarker assays, enabling earlier recognition of small airway injury and offering windows for timely intervention. At the same time, therapeutic strategies are evolving from broad immunosuppression toward regimen optimization that balances rejection prevention with infection risk mitigation and metabolic safety.

Procedural care has also modernized; bronchoscopy is increasingly used for both diagnostic refinement and targeted therapeutic delivery, while lung transplantation practices emphasize patient selection and perioperative immunomodulation to reduce chronic graft dysfunction. Pulmonary rehabilitation programs are being reimagined to support long-term functional recovery across inpatient and outpatient settings, with integrated telehealth and home-based components enhancing accessibility.

Commercially and operationally, delivery mode innovations such as advanced inhalation platforms and controlled infusion systems are improving adherence and pharmacokinetic control. These shifts are accompanied by evolving distribution architectures that prioritize hospital pharmacies for acute care and online and retail channels for ongoing outpatient management. Taken together, these developments are reshaping clinical algorithms, payer dialogues, and product development priorities across the ecosystem.

Assessing how changes in trade policies and tariff regimes are compelling supply chain redesign, localized sourcing, and procurement resilience for critical pulmonary care inputs

Recent tariff actions and trade policy adjustments have introduced new considerations for cross-border supply chains and procurement strategies that affect therapeutics, medical devices, and specialty equipment used in bronchiolitis obliterans syndrome care. Import duties and customs procedures can influence sourcing decisions for inhalation devices, intravenous infusion pumps, and specialized graft preservation materials, thereby affecting product availability and procurement timelines. As a result, institutions and manufacturers are reassessing manufacturing footprints and supplier diversification to maintain continuity of care.

Furthermore, tariff-driven cost pressures can accelerate localization strategies, encouraging partnerships with regional manufacturers and contract packaging organizations to reduce exposure to import volatility. In parallel, logistics providers and distributors are adapting inventory management and lead-time forecasting to buffer clinical supply lines against policy fluctuations. These operational adaptations frequently manifest as increased emphasis on dual sourcing, local regulatory alignment, and selective stockpiling for critical items used in perioperative transplant and long-term therapeutic regimens.

Importantly, regulatory harmonization and predictable customs valuation remain essential to minimizing downstream impacts on patient care. Stakeholders should therefore prioritize contractual flexibility, robust supplier qualification, and advanced scenario planning to sustain clinical operations and ensure that therapeutic continuity is preserved despite tariff-related disruptions.

A granular segmentation-driven perspective connecting therapeutic classes, procedural pathways, delivery formats, care settings, and distribution networks to reveal intervention points

A nuanced segmentation framework illuminates where clinical demand, procurement urgency, and therapeutic innovation intersect across drug classes, procedure types, delivery modes, end users, and distribution channels. Within drug classes, corticosteroids remain core and are differentiated between inhaled and systemic formulations, while immunosuppressants require distinction between antimetabolites and calcineurin inhibitors; macrolide usage reflects differing clinical rationale for azithromycin versus clarithromycin. Procedure types span bronchoscopy for surveillance and intervention, lung transplantation with single and double lung considerations, and pulmonary rehabilitation offered in both inpatient and outpatient formats to support functional recovery.

Delivery modes shape therapeutic reach and adherence, encompassing inhalation modalities through inhalers and nebulizers, intravenous administration via bolus and infusion approaches, and oral therapies delivered as capsules or tablets. End-user segmentation underscores the roles played by ambulatory surgery centers-whether hospital owned or independent-hospitals that vary between private and public settings, and specialty clinics such as pulmonology clinics and transplant centers that concentrate longitudinal care expertise. Distribution channels bridge clinical supply with patient access, including hospital pharmacies for inpatient and outpatient dispensing, online pharmacies divided between over-the-counter e-pharmacies and prescription-focused e-pharmacies, and retail pharmacies where chain and independent formats coexist.

Together, these intersecting segments create targeted opportunities for clinical optimization, commercial deployment, and policy alignment by revealing points of high clinical value and logistical complexity across the care continuum.

Regional nuances in clinical networks, regulatory pathways, and supply chain realities that shape access and implementation strategies across global healthcare zones

Regional dynamics materially influence clinical practice patterns, regulatory pathways, reimbursement structures, and supply chain strategies across the Americas, Europe Middle East & Africa, and Asia Pacific. In the Americas, clinical networks often concentrate transplant expertise in specialized centers, supporting integrated perioperative care and robust use of surveillance bronchoscopy, while commercial and reimbursement environments encourage both in-hospital and ambulatory delivery of long-term therapies. In contrast, Europe Middle East & Africa demonstrates heterogeneity in regulatory frameworks and reimbursement mechanisms, requiring adaptable clinical evidence packages and regional engagement to address diverse health system priorities.

Asia Pacific offers a varied landscape where rapid infrastructure development coexists with differing levels of transplant capacity and outpatient service access; this region is notable for its manufacturing strengths and potential for localized device and pharmaceutical partnerships. Across all regions, the interplay between procedural capability, access to rehabilitation services, and distribution logistics shapes patient pathways. Transitional care models and telemedicine programs are emerging as cross-regional solutions to bridge geographic barriers and enhance long-term monitoring return on investment.

Understanding these regional nuances helps stakeholders prioritize clinical trial site selection, supply chain redundancy, and stakeholder engagement strategies to align product development and delivery with local care realities.

Corporate archetypes, collaborative models, and evidence-driven differentiation strategies that are defining competitive dynamics and supply resilience in chronic airway care

Key company dynamics in the bronchiolitis obliterans syndrome space reflect a blend of pharmaceutical innovators, device manufacturers, diagnostics developers, specialized contract manufacturers, and leading transplant and pulmonology centers. Pharmaceutical developers are refining immunomodulatory regimens and exploring repurposed agents to manage chronic airway inflammation while device manufacturers invest in inhalation platforms and bronchoscopy technologies that enhance targeted delivery and diagnostic yield. Diagnostics firms are advancing biomarkers and assay platforms aimed at earlier detection of graft injury, which has implications for therapeutic timing and clinical trial design.

Contract manufacturers and regional production partners play a strategic role in supporting supply continuity, especially when import dependencies are challenged by trade policy shifts. Meanwhile, leading clinical centers and specialty clinics act as centers of excellence for protocol development, real-world evidence generation, and adoption pathways. Strategic collaborations among these stakeholders often prioritize co-development, shared data initiatives, and integrated care solutions that combine therapeutics with device-enabled monitoring and rehabilitation services.

Collectively, these company archetypes and collaborative models indicate that future differentiation will depend on evidence generation, integrated solution offerings, and supply chain agility that aligns with clinical imperatives and payer expectations.

Actionable strategic priorities for leaders to align surveillance-led clinical pathways, supply chain resilience, and integrated solution development to improve long-term outcomes

Industry leaders should prioritize integrated strategies that align clinical evidence, supply chain resilience, and stakeholder engagement to drive meaningful improvements in patient outcomes. First, invest in multimodal surveillance approaches that combine physiologic testing, imaging, and emerging biomarkers to enable earlier, evidence-informed interventions. Second, optimize therapeutic regimens by evaluating delivery modes that enhance adherence and therapeutic index, with particular attention to inhalation systems and controlled infusion technologies.

Operationally, companies and health systems should diversify supplier networks and pursue regional manufacturing partnerships to mitigate trade-related disruptions and shorten lead times for critical devices and therapeutics. Additionally, align commercial strategies with care delivery realities by engaging transplant centers, pulmonology clinics, and rehabilitation providers in co-development and educational initiatives. From a market access perspective, build robust health economic narratives and real-world evidence packages that demonstrate longitudinal benefits of surveillance-driven interventions and integrated care pathways.

Finally, foster cross-sector collaborations that link diagnostics, therapeutics, and digital monitoring into cohesive offerings. By doing so, leaders can improve clinical outcomes, streamline care transitions, and create differentiated value propositions that resonate with clinicians, payers, and patients alike.

A multi-method research approach combining literature synthesis, expert interviews, and structured triangulation to validate clinical, operational, and segmentation insights

This research adopted a multi-methodology approach combining rigorous secondary literature review, targeted primary interviews with clinical and supply chain experts, and structured data synthesis to ensure analytical rigor and practical relevance. Secondary sources included peer-reviewed clinical studies, professional society guidelines, regulatory documents, and technical specifications for devices and therapeutics. These materials were used to develop an evidence baseline and to identify areas requiring primary validation.

Primary research comprised semi-structured interviews with transplant surgeons, pulmonologists, pharmacy directors, procurement leads, and device engineers to capture operational realities, care pathway variations, and unmet needs. Data triangulation was applied across multiple inputs to reconcile clinical practice diversity and to validate segmentation frameworks that span drug classes, procedure types, delivery modes, end users, and distribution channels. Quality controls included source verification, de-duplication of evidence, and methodological transparency regarding inclusion criteria.

Finally, scenario analyses and sensitivity checks were used to explore operational implications of supply chain disruptions and policy shifts. The methodology emphasizes reproducibility, stakeholder validation, and clear documentation of assumptions to support confident decision-making based on the report's insights.

Conclusive synthesis emphasizing integration of early detection, targeted therapies, and resilient delivery systems to preserve lung function and enhance patient-centered outcomes

In sum, bronchiolitis obliterans syndrome demands a coordinated response that links early detection, targeted therapy, and resilient delivery systems. Clinical progress is being driven by improved surveillance modalities and more nuanced therapeutic strategies that balance immunomodulation with safety considerations. At the same time, procedural innovations and rehabilitation programs are enhancing patient recovery pathways, and delivery mode advancements are improving adherence and dosing precision.

Operational and commercial stakeholders must contend with supply chain complexity and policy volatility, which underscore the need for diversified sourcing and regional manufacturing partnerships. Segmentation clarity across drug classes, procedures, delivery modes, end-user settings, and distribution channels provides a practical blueprint for aligning product development, clinical adoption, and access strategies. Ultimately, the most impactful interventions will integrate diagnostics, therapeutics, and care delivery models to preserve lung function and quality of life for affected patients.

This conclusion underscores the opportunity for coordinated clinical and commercial efforts to translate evolving science into durable improvements in long-term outcomes and patient-centered care pathways.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bronchiolitis Obliterans Syndrome Market, by Drug Class

  • 8.1. Corticosteroids
    • 8.1.1. Inhaled
    • 8.1.2. Systemic
  • 8.2. Immunosuppressants
    • 8.2.1. Antimetabolites
    • 8.2.2. Calcineurin Inhibitors
  • 8.3. Macrolides
    • 8.3.1. Azithromycin
    • 8.3.2. Clarithromycin

9. Bronchiolitis Obliterans Syndrome Market, by Procedure Type

  • 9.1. Bronchoscopy
  • 9.2. Lung Transplantation
  • 9.3. Pulmonary Rehabilitation

10. Bronchiolitis Obliterans Syndrome Market, by Delivery Mode

  • 10.1. Inhalation
    • 10.1.1. Inhalers
    • 10.1.2. Nebulizers
  • 10.2. Intravenous
    • 10.2.1. Bolus
    • 10.2.2. Infusion
  • 10.3. Oral
    • 10.3.1. Capsules
    • 10.3.2. Tablets

11. Bronchiolitis Obliterans Syndrome Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics
    • 11.3.1. Pulmonology Clinics
    • 11.3.2. Transplant Centers

12. Bronchiolitis Obliterans Syndrome Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Bronchiolitis Obliterans Syndrome Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bronchiolitis Obliterans Syndrome Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bronchiolitis Obliterans Syndrome Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Bronchiolitis Obliterans Syndrome Market

17. China Bronchiolitis Obliterans Syndrome Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Astellas Pharma Inc.
  • 18.6. Bristol-Myers Squibb Company
  • 18.7. F. Hoffmann-La Roche Ltd
  • 18.8. GlaxoSmithKline plc
  • 18.9. Mallinckrodt plc
  • 18.10. Merck & Co., Inc.
  • 18.11. Novartis AG
  • 18.12. Omron Corporation
  • 18.13. PARI GmbH
  • 18.14. Pfizer Inc.
  • 18.15. Sanofi S.A.
  • 18.16. Sensirion AG
  • 18.17. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SYSTEMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SYSTEMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY AZITHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY AZITHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CLARITHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CLARITHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CLARITHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BRONCHOSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BRONCHOSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BRONCHOSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY LUNG TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY LUNG TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY LUNG TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PULMONARY REHABILITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PULMONARY REHABILITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PULMONARY REHABILITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BOLUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BOLUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BOLUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PULMONOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PULMONOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PULMONOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TRANSPLANT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TRANSPLANT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TRANSPLANT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 222. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 223. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 224. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 225. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 228. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 232. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 262. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 263. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 264. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 266. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 267. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 268. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 269. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 271. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 274. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 275. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 276. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 277. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 279. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 280. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 281. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 282. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 284. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (U